单克隆抗体在晚期胃癌免疫治疗中的研究进展

Immunotherapy of advanced gastric cancer:advances in monoclonal antibodies

胃癌是常见的恶性肿瘤之一,大多数胃癌就诊已是晚期。单克隆抗体能特异性抑制和杀伤肿瘤细胞,毒副作用小。目前,单克隆抗体如抗表皮生长因子-1(EGFR1)单抗和抗人表皮生长因子-2(HER-2)单抗、抗血管内皮生长因子(VEGF)单抗、抗程序性细胞死亡蛋白-1(PD-1)和抗PD-L1单抗等成为晚期胃癌免疫治疗中的热点,并逐渐应用于临床实践。本文就近年来以上几种单抗的作用机制和对晚期胃癌的临床疗效研究作一简要综述,为今后治疗胃癌的单抗类药物的研发及临床应用提供依据。

Gastric cancer is one of the common malignant tumors in China.Most gastric cancers are discovered at the late stage.Monoclonal antibody can inhibit and kill cancer cells specifically,with less toxic and side effects.Re⁃cently,monoclonal antibodies such as anti-epidermal growth factor receptor 1(EGFR1)antibody,anti-HER-2 antibody,anti-vascular endothelial growth factor(VEGF)antibody,anti-programmed death protein-1(PD-1)and anti-PD-L1 anti⁃body have been developed and applied.Monoclonal antibody therapy has become a hot spot in the immunotherapy of ad⁃vanced gastric cancer.Herein,the action mechanisms and clinical efficacy of various monoclonal antibodies for the treat⁃ment of advanced gastric cancer are reviewed,so as to provide a reference for future research,development and clinical application of monoclonal antibodies for the treatment of gastric cancer.